Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (61-70 of 322) with videos related to

Pageof 33
Sort By:
Leukemia & Lymphoma|November 5, 2019
Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemiaBenjamin A Derman, Mitchell Streck, Joseph Wynne, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 6, 2023
Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understandingAmani Alqahtani, Diala Alhousari, Amir Ali, et al.
Leukemia|December 28, 2023
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALLGeoffrey Parriott, Emma Hegermiller, Rosemary E Morman, et al.
Bone Marrow Transplantation|May 8, 2020
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromeJennifer H Cooperrider, Noreen Fulton, Andrew S Artz, et al.
Blood|May 27, 2008
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesWendy Stock, Mei La, Ben Sanford, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemiaGeoffrey Parriott, Emma Hegermiller, Rosemary E Morman, et al.
Translational Oncology|October 27, 2015
Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL)Martin Mutonga, Kenji Tamura, Gregory Malnassy, et al.
Leukemia & Lymphoma|January 15, 2009
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemiaXavier Poiré, Andrew Artz, Richard A Larson, et al.
British Journal of Haematology|December 11, 2023
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitorsRafael Madero-Marroquin, Adam S DuVall, Caner Saygin, et al.
Leukemia & Lymphoma|February 9, 2021
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literatureAjay Major, Jennifer Collins, Caroline Craney, et al.
Pageof 33

Showing results (61-70 of 322) with videos related to

Sort By:
Pageof 33
Leukemia & Lymphoma|November 5, 2019
Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemiaBenjamin A Derman, Mitchell Streck, Joseph Wynne, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 6, 2023
Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understandingAmani Alqahtani, Diala Alhousari, Amir Ali, et al.
Leukemia|December 28, 2023
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALLGeoffrey Parriott, Emma Hegermiller, Rosemary E Morman, et al.
Bone Marrow Transplantation|May 8, 2020
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromeJennifer H Cooperrider, Noreen Fulton, Andrew S Artz, et al.
Blood|May 27, 2008
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesWendy Stock, Mei La, Ben Sanford, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemiaGeoffrey Parriott, Emma Hegermiller, Rosemary E Morman, et al.
Translational Oncology|October 27, 2015
Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL)Martin Mutonga, Kenji Tamura, Gregory Malnassy, et al.
Leukemia & Lymphoma|January 15, 2009
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemiaXavier Poiré, Andrew Artz, Richard A Larson, et al.
British Journal of Haematology|December 11, 2023
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitorsRafael Madero-Marroquin, Adam S DuVall, Caner Saygin, et al.
Leukemia & Lymphoma|February 9, 2021
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literatureAjay Major, Jennifer Collins, Caroline Craney, et al.
Pageof 33